Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting
Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held in Stockholm, Sweden from July 17 - 20, 2024.
Adverum Biotechnologenies, Inc.（納斯達克股票代碼：ADVM）是一家率先使用基因療法作爲高度流行的眼部疾病新護理標準的臨床階段公司，該公司今天宣佈，該公司將在美國發表爲期26周的具有里程碑意義的中期分析，該研究旨在治療溼性年齡相關黃斑變性（溼性AMD）。視網膜專家協會（ASRS）年度科學會議將於2024年7月17日至20日在瑞典斯德哥爾摩舉行。
ASRS Annual Scientific Meeting Presentation Information
ASRS 年度科學會議演示信息
Title: Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
標題：新生血管 AMD 的 Ixoberogene Soroparvovec (ixo-VEC) IVT 基因療法：LUNA 2 期研究的首次 26 週中期分析結果
Date / Time: Wednesday, July 17th, 2024 at 8:45am CEST
日期/時間：歐洲中部標準時間 2024 年 7 月 17 日星期三上午 8:45
Session: Wet AMD Symposium 1
會議：溼式 AMD 研討會 1
Presenter: Charles C. Wykoff, MD, PhD, FASRS, Director of Research, Retina Consultants of Texas; Professor of Clinical Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital
主持人：Charles C. Wykoff，醫學博士，FASRS，德克薩斯州視網膜顧問研究總監；休斯敦衛理公會醫院布蘭頓眼科研究所臨床眼科教授
The presentation will be available on the News and Publications section of Adverum's website shortly after the presentation.
演示結束後不久，該演示文稿將在Adverum網站的新聞和出版物欄目上發佈。